ACET

Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management